Switzerland · Delayed Price · Currency is CHF Alcon Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 delivered 6% sales growth, driven by innovation in surgical equipment, IOLs, and dry eye. Guidance for 2026 remains 5–7% sales growth and 10–13% EPS growth, with margin expansion expected in H2. Robust pipeline and capital returns support long-term growth.
-
Focused on eye care innovation, the business is launching multiple new products, including the UNITY surgical platform and advanced IOLs, to drive efficiency and growth. Strong free cash flow supports ongoing R&D and disciplined M&A, while robust markets and margin expansion are expected despite tariff pressures.
Fiscal Year 2025
-
Q4 and full-year 2025 saw strong sales growth and innovation-driven momentum, with equipment and dry eye portfolios outperforming. 2026 guidance anticipates 5–7% sales growth, margin expansion, and continued investment in new products, despite tariff and market headwinds.
-
Q3 2025 delivered 5% sales growth, driven by strong Equipment and Ocular Health performance, with Unity VCS and PanOptix Pro launches gaining traction. Full-year guidance is reaffirmed, but tariff pressures and competitive markets remain key risks.
-
Seven new products and five acquisitions have driven strong portfolio expansion, with the Unity platform and Retina machine set to boost equipment and consumables growth. The cataract and contact lens markets remain stable, while the STAAR acquisition and new product launches are expected to drive future growth. Margin expansion is anticipated despite tariff headwinds.
-
Q2 sales grew 3% year-over-year to $2.6B, with vision care outperforming surgical amid soft market conditions. Major product launches and acquisitions, including STAAR and LumiThera, are expected to drive growth, while full-year guidance was revised to reflect market softness and FX headwinds.
-
Q1 2025 saw 3% sales growth to $2.5B, with strong launches of UNITY VCS and PanOptix Pro, and robust international performance offsetting U.S. softness. 2025 guidance was updated to $10.4–$10.5B revenue and 6–7% constant currency growth, with H2 acceleration expected from new products.
-
Management outlined a five-year plan targeting 6%-8% annual revenue growth and 12%-15% EPS growth, driven by increased R&D investment, a robust innovation pipeline, and operational excellence. Key launches include Unity VCS, PanOptix Pro, Precision7, and AR-15512, with strategic M&A like Aurion Biotech and LENSAR enhancing the portfolio.
-
A robust innovation pipeline is driving multiple new product launches in eye care, including advanced contact lenses, dry eye therapies, and surgical platforms. Operational efficiency, margin improvement, and global expansion remain key priorities, with a strong focus on R&D and disciplined capital allocation.
Fiscal Year 2024
-
2024 saw 6% sales growth to $9.8B, record free cash flow, and strong international performance offsetting U.S. softness. 2025 guidance targets 6–8% constant currency growth, margin expansion in H2, and major product launches in Surgical and Vision Care.
-
Q3 sales grew 6% to $2.4B with EPS up 25% and record free cash flow. International and innovative product launches offset U.S. softness. Full-year guidance was tightened, with strong growth expected from new products and international markets.
-
Sales rose 6% to $2.5B, with strong growth in contact lenses, implantables, and Systane. Guidance for 2024 is maintained, with new product launches and international expansion expected to drive future growth. FX and inventory provisions present headwinds.